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A commentary on 
Acute tension-type headaches are associated with impaired cogni tive function and more nega-
tive mood
by Smith AP. Front Neurol (2016) 7:4. doi: 10.3389/fneur.2016.00042
I found Smith’s article (1) extremely interesting. The author reported that an acute attack of tension-
type headache (TTH) may be “associated with an increase in negative affect, poorer performance 
on working memory and semantic memory tasks, slower psychomotor performance, and increased 
distraction from irrelevant stimuli” (1).
Although there are a number of articles dealing with cognition/behavior in headache patients 
(2–4), there is still a consensus that the two most frequent primary headaches, migraine and TTH (5), 
do not significantly affect cognitive functions to a degree that daily activities are seriously affected, 
particularly when one considers the interictal periods.
It is well known that migraine attacks are incapacitating, whereas the TTH attacks are mild or 
moderate in intensity, not affecting the activities of everyday life. In fact, patients with TTH may 
suffer severe headache attacks, resulting in impairment of routine activities. In a study carried out 
in our university (6), involving 121 female nurses, 536 headache attacks were registered, 117 with 
features of TTH and 10 of probably TTH, 3 of these 127 attacks (2.4%) were considered severe.
Considering that headache attacks are relatively frequent, and the fact that they may impair 
cognitive function, the physician should consider prophylactic measures to avoid triggering attacks 
during the performance of important tasks, in particular, those that demand a high level of attention 
and precision.
The interesting results obtained by Smith (1) need, however, to be confirmed by other works with 
a larger number of subjects. In addition, the current different treatments that may be used as preven-
tive forms to control the TTH attacks are usually not corroborated by evidence-based medicine.
When we are dealing with children suffering from TTH, which are regarded as a prevalent and 
debilitating condition for both child and his or her family, the parents are often reluctant to accept a 
prescription with a pharmacological agent (7). They tend to prefer a non-pharmacological treatment 
as their first choice (7). One of the approaches to be tried in children is to stimulate a healthy lifestyle 
in order to avoid factors that could trigger headaches at both home and school (e.g., a good quality 
FIGUre 1 | Pharmacological and non-pharmacological strategies that may be adopted to reduce the possibility of a tension-type headache attack, 
which may impair cognitive function, representing a major cause of concern, when the individual is engaged in activities that demand an 
optimization of performance.
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of sleep, adequate water and food ingestion, physical activity, and 
learning how to cope with psychosocial stressors) (7).
There are various other non-pharmacological strategies that 
may be adopted to reduce the possibility of a headache attack 
(Figure  1). Acupuncture, manipulation, joint range of motion, 
massage, cold packs, home exercise programs, advice on pos-
ture, muscle stretching techniques, retraining, and razor are 
some alternatives that might be of use (8). A recent update of 
a Cochrane review concluded that acupuncture is effective for 
treating frequent episodic or chronic TTHs (9).
Since the major concern here is the cognitive impairment dur-
ing headache attacks, the use of preventive drugs to avoid such 
crises must bear in mind a possible additional cognitive deficit 
triggered by the choice of medication. The most widely used 
drug for treating TTH is amitriptyline, which, although it may 
attenuate a negative mood, can in fact worsen the cognitive symp-
tomatology (10). There are a number of other pharmacological 
agents that have been employed as prophylactic treatment, such 
as antiepileptic drugs (sodium valproate, topiramate, and gabap-
entin), benzodiazepines, botulinum toxin, noradrenergic and 
specific serotonergic antidepressants (mirtazapine), serotonin 
re-uptake inhibitor antidepressants, and other tricyclic antide-
pressants (11); however, memory impairment has been reported 
with some of them.
A recent review (12) concluded that, in epileptic patients, 
some antiepileptic drugs, namely phenobarbital, phenytoin, 
topiramate, and zonisamide, can impair cognitive function. 
On the other hand, sodium valproate, carbamazepine, gabap-
entin, and oxcarbazepine do not appear to affect cognition. 
In addition, phenobarbital, valproate, gabapentin, topiramate, 
levetiracetam, and zonisamide may produce adverse behavioral 
side effects, although carbamazepine was considered neutral by 
the authors (12).
Nevertheless, venlafaxine and SSRIs were no more effective 
than amitriptyline or placebo in reducing the attack frequency in 
chronic TTH (13).
Recent evidence suggests that it is indeed possible to protect 
cognitive functioning by pharmacoterapy, despite the fact that 
its effectiveness has not been demonstrated to date in children 
or adolescents. The newly introduced drugs, levetiracetam and 
lamotrigine, seem to induce positive cognitive effects, with an 
additional positive behavioral effect being observed with the 
latter.
Topiramate is another drug widely used to prevent migraine 
and has also been used to treat chronic TTH, but it is well 
established that it can cause a major deterioration in cognition 
(particularly in relation to verbal fluency, memory spans, and 
working memory) (14). Since levetiracetam may improve cogni-
tive abilities, it was tried to overcome the cognitive impairment 
induced by topiramate using it in combination with levetiracetam. 
Unfortunately, they were unsuccessful, using an experimental 
model with rats (15). In this context, a small series of patients with 
topiramate-related cognitive and language dysfunction improved 
with donepezil (16).
The ethical, legal, and public policy implications of the use 
of drugs, such as donepezil, rivastigmine, galantamine, caffeine, 
nicotine, amphetamines, modafinil, and memantine to enhance 
cognition in cognitively healthy individuals is reviewed by 
Mehlman (17). In this concern, memantine (18) and dextroam-
phetamine (19) were used for prophylaxis of chronic TTH.
Over-the-counter medications are largely used in the acute 
therapy for TTH (20). A recent review reported that the number 
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needed to treat values for being pain-free at 2 h compared with 
placebo were 8.7, 8.9, and 9.8, respectively, for paracetamol 
1,000 mg, ibuprofen 400 mg, and ketoprofen 25 mg (21).
Another possible form to treat acute TTH in adults and 
children above 6 years is the local topical use of 10% peppermint 
oil in ethanol, whose beneficial effects are comparable to that of 
paracetamol or acetylsalicylic acid (22).
In conclusion, in the future, new drugs are likely to be intro-
duced or the agents in the current therapeutic arsenal are to 
be used in combination in order to overcome possible adverse 
cognitive and/or behavioral side effects that might occur during 
preventive therapy in patients with incapacitating headaches. 
Headache attacks can indeed impair cognitive function, repre-
senting a major cause of concern, since these individuals may be 
engaged in activities, such as driving, flying an aircraft, taking an 
important examination, etc., which demand an optimization of 
performance. Thus, the physician should consider prophylactic 
measures to avoid triggering attacks during the performance of 
such tasks.
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